Summary of Verastem Oncology Q1 2026 Earnings Call

1Key Financial Results and Metrics

Net Product Revenue: $18.7 million for Q1 2026, contributing to nearly $50 million since the launch of AVMAPKI FAKZYNJA CO-PACK.

Cost of Sales: $2.8 million, aligned with revenue growth.

Research and Development Expenses: $38.2 million, driven by ongoing clinical trials, particularly for VS-7375.

Selling, General & Administrative Expenses: $22.3 million, expected to remain stable throughout 2026.

Non-GAAP Adjusted Net Loss: $42.7 million ($0.43 per share diluted), slightly improved from $42.9 million ($0.79 per share diluted) in Q1 2025.

Cash Position: $181.7 million at the end of Q1 2026, projected to fund operations into the first half of 2027.

2Strategic Updates and Business Highlights

Product Launch: Continued growth in the prescriber base and patient starts for AVMAPKI FAKZYNJA CO-PACK, with over 400 unique prescribers.

Leadership Changes: Appointment of Dan Lyons as Chief Commercial Officer to enhance commercialization strategies.

Clinical Development: Progress in the VS-7375 Target-D clinical trial program, with ongoing Phase I/II trials and initiation of Phase II registration-directed trials in pancreatic cancer, non-small cell lung cancer, and colorectal cancer.

Market Strategy: Focus on optimizing patient identification and treatment initiation to enhance therapy uptake and adherence.

3Forward Guidance and Outlook

Self-Sustainability: The LGSOC franchise is expected to become self-sustaining in the second half of 2026, with CO-PACK revenues supporting ongoing operations and clinical trials.

Growth Potential: Anticipated increase in revenue from CO-PACK as the company implements strategic changes to drive patient adoption and retention.

4Bad News, Challenges, or Points of Concern

Seasonal Headwinds: Q1 performance was impacted by insurance turnover, severe weather affecting patient access, and early discontinuations among patients with advanced disease.

Market Dynamics: Some patients were found to be further along in their treatment journey than expected, leading to earlier treatment discontinuations.

Patient Management: The need for ongoing education around treatment protocols and managing side effects to improve patient retention on therapy.

5Notable Q&A Insights

Partnership and Interest in VS-7375: Potential partners are looking for robust U.S. data to gauge the asset's competitiveness in the market.

Self-Sustainability Details: SG&A and R&D expenses are expected to stabilize, with a focus on maintaining operational efficiency.

Clinical Data Expectations: The company aims for a comprehensive data set from ongoing trials by the end of the year, with an emphasis on overall response rates and durability for regulatory submissions.

Patient Anecdotes: Positive anecdotal evidence from physicians regarding long-term patient outcomes, including significant quality of life improvements for some patients on therapy. This summary encapsulates the key financial metrics, strategic initiatives, forward-looking statements, challenges faced, and insights from the Q&A session during Verastem Oncology's Q1 2026 earnings call.